Press Releases Sanofi

Equities

SAN

FR0000120578

Pharmaceuticals

Real-time Euronext Paris Other stock markets 04:08:15 2025-07-10 am EDT			5-day change	1st Jan Change
84.04 ^EUR	+0.86%		+1.92%	-10.34%

Jul. 08	SANOFI : UBS maintains a Buy rating	ZD
Jul. 03	SANOFI : Goldman Sachs reiterates its Neutral rating	ZD

Press Releases

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juin 2025	Jul. 09	PU
Press release: Availability of the Q2 2025 Aide mémoire	Jun. 30	GL
Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy	Jun. 30	GL
Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts	Jun. 26	PR
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation	Jun. 25	GL
Sanofi : Déclaration des transactions sur actions propres	Jun. 24	PU
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma	Jun. 23	GL
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid	Jun. 20	GL
Press release: Sanofi successfully prices €1.5 billion bond issue	Jun. 17	GL
Sanofi: Disclosure of trading in own shares	Jun. 16	PU
SNY Investors Have Opportunity to Join Sanofi Fraud Investigation with the Schall Law Firm	Jun. 16	BU
Sanofi - EAACI, Dupixent demonstrated superiority over Xolair in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	Jun. 16	AQ
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	Jun. 15	PU
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study	Jun. 15	GL
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mai 2025	Jun. 09	PU
Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care	Jun. 09	AQ
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season	Jun. 09	GL
Media Update: RAD: Dupixent data reinforce use in atopic dermatitis patients with skin of color	Jun. 07	PU
Sanofi: Disclosure of trading in own shares	Jun. 06	PU
Media Update: ISTH: new data highlight innovation from Sanofi’s pipeline in rare diseases	Jun. 06	PU
Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan	Jun. 05	GL
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector	Jun. 03	PU
Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector	Jun. 03	GL
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease	Jun. 03	GL
Sanofi acquires Blueprint Medicines for $9.1 billion	Jun. 02	AQ